Mar 4, 2025 · BeiGene is a global, science-driven oncology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.

Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.. Vision. Transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world.

The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, harnessing the body’s immune system to attack tumors, and targeting specific biomarkers of cancer. The tilted angle of the button embodies our path …

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. In addition to leveraging our internal research resources, we continually evaluate external early-stage assets that might enhance our pipeline and opportunities.

Xiaodong Wang, Ph.D. is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang has been on the Board of Directors since February 2016. Dr. Wang is the founding Director of the National Institute of Biological Sciences in Beijing, serving since 2003, and became its Director and Investigator in 2010.

We have received reports of an employment scam where individuals are falsely representing themselves as BeiGene HR representatives and conducting bogus “employment interviews” via email, including using videotaped answers on Flock, and ultimately requesting payment as a condition for receiving an offer of employment.

Learn more about our U.S. FDA approved medications including Brukinsa and Tevimbra. Download full prescribing information and patient information.

Poster Presentation (#1649) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: Results from the phase 1 CaDAnCe-101 study Presenting Author: Constantine S. Tam Date / Time (PST): Saturday, December 7, 2024 5:30 - 7:30 PM Location: Convention Center, Halls G …

Nov 14, 2024 · “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone.

3 days ago · Sustainability at our core. Change Is The Cure is our sustainability and corporate social responsibility platform. It delivers on our mission and codifies the work we are doing to go beyond our life-saving medicines to meet the diverse needs of the global population – from patients and colleagues to investors and the communities in which we serve.